暂无数据
关于我们
意见反馈
$ 0.2649
+0.0121(4.7864%)
05-19 11:14
Tyme Technologies, Inc.
| 最高：0.2700 | 今开：0.2500 | 成交量：42.15万股 | 换手：0.24% |
| 最低：0.2500 | 昨收：0.2528 | 成交额：11.12万 | 振幅：7.91% |
| 52周最高：2.0200 | 量比：0.58 | 市盈率(TTM)：亏损 | 市净率：0.53 |
| 52周最低：0.2187 | 委比：42.86% | 市盈率(静)：亏损 | 市销率：-- |
| 每股收益：-0.14 | 股息(TTM)：-- | 每手股数：1 | 总市值：4561.76万 |
| 每股净资产：0.50 | 股息率(TTM)：-- | 最小价差：0.0001 | 总股本：1.72亿 |
| 机构持股：-- | Beta：-- | 空头回补天数：-- | 货币单位：USD |
财务指标
|
单位:美元
|
2018-06-30
|
2018-03-31
|
2017-12-31
|
2017-09-30
|
2017-06-30
|
|
流动资产
|
2,346.87万
|
3,101.46万
|
1,260.06万
|
869.64万
|
1,178.39万
|
|
现金及短期投资
|
2,243.86万
|
2,897.58万
|
1,080.58万
|
751.34万
|
1,050.18万
|
|
短期应收账款
|
--
|
--
|
--
|
--
|
--
|
|
存货
|
--
|
--
|
--
|
--
|
--
|
|
其他流动资产
|
103.01万
|
203.88万
|
179.49万
|
118.29万
|
128.21万
|
|
非流动资产
|
160.59万
|
3,239.00
|
4,313.00
|
5,387.00
|
6,461.00
|
|
厂房及设备净资产
|
1.64万
|
3,239.00
|
4,313.00
|
5,387.00
|
6,461.00
|
|
项目总投资及垫款
|
--
|
--
|
--
|
--
|
--
|
|
长期应收票据
|
--
|
--
|
--
|
--
|
--
|
|
无形资产
|
--
|
--
|
--
|
--
|
--
|
|
递延所得税资产
|
--
|
--
|
--
|
--
|
--
|
|
其他资产
|
158.94万
|
--
|
--
|
--
|
--
|
|
合计总资产
|
2,507.46万
|
3,101.78万
|
1,260.50万
|
870.17万
|
1,179.04万
|
|
流动负债
|
298.70万
|
454.59万
|
371.38万
|
305.19万
|
321.44万
|
|
短期债务（含部分LTD）
|
26.93万
|
48.01万
|
--
|
--
|
--
|
|
应付账款
|
124.43万
|
--
|
--
|
--
|
--
|
|
应付所得税
|
--
|
--
|
--
|
--
|
--
|
|
其他流动负债
|
147.33万
|
406.58万
|
371.38万
|
305.19万
|
321.44万
|
|
非流动负债
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
长期负债
|
--
|
--
|
--
|
--
|
--
|
|
拨备风险及费用
|
--
|
--
|
--
|
--
|
--
|
|
递延所得税负债
|
--
|
--
|
--
|
--
|
--
|
|
其他负债
|
--
|
--
|
--
|
--
|
--
|
|
合计总负债
|
298.70万
|
454.59万
|
371.38万
|
305.19万
|
321.44万
|
|
股东权益合计
|
2,208.76万
|
2,647.20万
|
889.11万
|
564.99万
|
857.59万
|
|
非股权储备
|
--
|
--
|
--
|
--
|
--
|
|
优先股-账面价值
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
普通股权益（合计）
|
2,208.76万
|
2,647.20万
|
889.11万
|
564.99万
|
857.59万
|
|
累计少数股东权益
|
--
|
--
|
--
|
--
|
--
|
|
权益总额
|
2,208.76万
|
2,647.20万
|
889.11万
|
564.99万
|
857.59万
|
|
负债与股东权益合计
|
2,507.46万
|
3,101.78万
|
1,260.50万
|
870.17万
|
1,179.04万
|
|
每股账面价值
|
0.22
|
0.26
|
0.10
|
0.06
|
0.10
|
|
每股账面价值-有形
|
0.22
|
0.26
|
0.10
|
0.06
|
0.10
|
|
单位:美元
|
2018-06-30
|
2018-03-31
|
2017-12-31
|
2017-09-30
|
2017-06-30
|
|
营业总收入
|
--
|
--
|
--
|
--
|
--
|
|
-营业成本
|
2,369.00
|
1,074.00
|
1,074.00
|
1,074.00
|
1,074.00
|
|
毛利
|
-2,369.00
|
-1,074.00
|
-1,074.00
|
-1,074.00
|
-1,074.00
|
|
-销售管理及行政费用
|
671.68万
|
531.21万
|
556.02万
|
529.58万
|
318.75万
|
|
-其他运营费用
|
--
|
--
|
--
|
--
|
--
|
|
计息税前利润
|
-671.92万
|
-531.31万
|
-556.13万
|
-529.69万
|
-318.86万
|
|
+非经营收入(支出)
|
--
|
--
|
--
|
--
|
31.56万
|
|
-非经常性支出
|
--
|
--
|
--
|
-7.48万
|
--
|
|
-利息支出
|
3,627.00
|
--
|
--
|
--
|
--
|
|
税前净利润
|
-672.28万
|
-531.31万
|
-556.13万
|
-522.22万
|
-287.29万
|
|
-所得税
|
--
|
--
|
--
|
--
|
--
|
|
+其他税后调整
|
0.00
|
0.00
|
0.00
|
0.00
|
0.00
|
|
+联署公司盈利权益
|
--
|
--
|
--
|
--
|
--
|
|
合并净利润
|
-672.28万
|
-531.31万
|
-556.13万
|
-522.22万
|
-287.29万
|
|
-少数股东权益开支
|
--
|
--
|
--
|
--
|
--
|
|
净利润
|
-672.28万
|
-531.31万
|
-556.13万
|
-522.22万
|
-287.29万
|
|
-优先股股息
|
--
|
--
|
--
|
--
|
--
|
|
一般可用收入净利润
|
-672.28万
|
-531.31万
|
-556.13万
|
-522.22万
|
-287.29万
|
|
每股基本收益
|
-0.07
|
-0.06
|
-0.06
|
-0.06
|
-0.03
|
|
摊薄每股收益
|
-0.07
|
-0.06
|
-0.06
|
-0.06
|
-0.03
|
|
息税折旧摊销前利润
|
-671.68万
|
-531.21万
|
-556.02万
|
-529.59万
|
-318.75万
|
|
单位:美元
|
2018-03-31
|
2017-03-31
|
2015-12-31
|
2014-11-30
|
|
净收益
|
-1,896.95万
|
-1,520.68万
|
-1,172.68万
|
-5.39万
|
|
+折旧损耗及摊稍
|
4,296.00
|
4,281.00
|
4,292.00
|
--
|
|
+递延税及投资税减免
|
--
|
--
|
--
|
--
|
|
+其他经营基金
|
729.89万
|
807.21万
|
472.46万
|
--
|
|
营运资金
|
-1,166.62万
|
-713.04万
|
-699.80万
|
-5.39万
|
|
+特别项目
|
--
|
--
|
--
|
--
|
|
+营运资金变动
|
-21.30万
|
126.93万
|
38.78万
|
-3,757.00
|
|
经营现金流
|
-1,187.93万
|
-586.11万
|
-661.02万
|
-5.77万
|
|
资本支出
|
--
|
--
|
--
|
--
|
|
收购所得净资产
|
--
|
--
|
--
|
--
|
|
固定资产和业务出售收入
|
--
|
--
|
--
|
--
|
|
投资买卖净额
|
--
|
--
|
--
|
--
|
|
非现金项目
|
0.00
|
0.00
|
0.00
|
0.00
|
|
投资现金流
|
--
|
--
|
--
|
--
|
|
发放现金股利
|
--
|
--
|
--
|
--
|
|
股本变动
|
3,019.71万
|
1,047.09万
|
723.10万
|
--
|
|
发行/削减债务净额
|
--
|
-23.21万
|
131.58万
|
--
|
|
其他融资基金
|
17.50万
|
--
|
250.00万
|
5.77万
|
|
筹资现金流
|
3,037.21万
|
1,023.88万
|
1,104.67万
|
5.77万
|
|
汇率影响
|
--
|
--
|
--
|
--
|
|
杂项基金
|
--
|
--
|
--
|
--
|
|
现金净流动
|
1,849.28万
|
437.77万
|
443.66万
|
--
|
|
自由现金流
|
-1,187.93万
|
-586.11万
|
-661.02万
|
-5.77万
|
公司高管
|
Timothy C. Tyson
|
Timothy C. Tyson is a businessperson who founded Thayer Leader Development Group, Inc. and who has been the head of 8 different companies. Currently, he is Chairman at Icagen-T, Inc., Chairman & Chief Executive Officer at Avara Pharmaceutical Services, Inc., Chairman & Chief Executive Officer at Avara Norman Pharmaceutical Services, Inc. (a subsidiary of Avara Pharmaceutical Services, Inc.), Chairman at Icagen, Inc. and President of Alkaloida Chemical Co. Ltd. Mr. Tyson is also on the board of Tyme Technologies, Inc., Tyme, Inc. and ICN Hungary Co. Ltd. and Chief Executive Officer-Roundtable at the University of California, Irvine.
In the past he was Executive Chairman of Laurus Labs Ltd., Vice President & General Manager at GlaxoSmithKline Plc and President-Global Manufacturing & Supply at Glaxo Wellcome Plc (a subsidiary of GlaxoSmithKline Plc), Operations Manager at Procter & Gamble Co., Chairman for Aptuit LLC, President & Chief Executive Officer for Valeant Pharmaceuticals International Corp. and Director-Leadership Forum at International Society for Pharmaceutical Engineering.
Mr. Tyson received an MBA and a graduate degree from Jacksonville State University and an undergraduate degree from US Military Academy.
|
|
Tommy George Thompson
|
Mr. Tommy G. Thompson is a Chairman at Vital Decisions LLC, a Chairman-Trustees Board at Physicians Realty Trust, a Chairman at TherapeuticsMD, Inc., an Independent Director at United Therapeutics Corp., an Independent Director at Centene Corp., a Chairman & Chief Executive Officer at Thompson Holdings, Inc., a Member at State Bar of Wisconsin, a Member at The District of Columbia Bar and an Operating Partner at Windrose Health Investors LLC. He is on the Board of Directors at Tyme Technologies, Inc., United Therapeutics Corp., Centene Corp., Accordia Global Health Foundation, Armada Media Corp., Cleveland HeartLab, Inc. and Medical Missions For Children, Inc. Mr. Thompson was previously employed as a Chairman by Stayhealthy, Inc., an Independent Director by Cytori Therapeutics, Inc., an Independent Director by Cancer Genetics, Inc., a Chairman by AGA Medical Holdings, Inc., an Independent Director by C.R. Bard, Inc. (New Jersey), a Chairman by AGA Medical Corp., a Chairman by CareView Communications, Inc., a Senior Partner by Akin, Gump, Strauss, Hauer & Feld LLP, an Independent Chairman by The Deloitte Center for Health Solutions, a Chairman by Logistics Health, Inc., a Chairman by The Global Fund to Fight AIDS, Tuberculosis & Malaria, a Secretary & Governor by US Department of Health & Human Services (DC), a Governor by State of Wisconsin, a Venture Partner by Burrill & Co. LLC, a Chairman by Education Commission of the States, a Chairman by Midwestern Governors Conference, and a Chairman by National Governors Association. He also served on the board at Tyme, Inc., Tenex Health, Inc., CNS Response, Inc., SpectraScience, Inc., Medco Health Solutions, Inc., PURE Bioscience, Inc., VeriChip Corp., Harmony Information Systems, Inc., Picis, Inc., ProCure Treatment Centers, Inc., Voyager Pharmaceutical Corp. and X-Shares Advisors LLC. He received his undergraduate degree from the University of Wisconsin and a graduate degree from the University of Wisconsin.
|
|
James Biehl
|
James Biehl is on the board of Tyme Technologies, Inc. and Member of American Bar Association, Member of New Jersey State Bar Association, Member of Philadelphia Bar Association, Member of Pennsylvania State Bar Association and Partner at Drinker Biddle & Reath LLP.
Mr. Biehl received a graduate degree from Temple University (Pennsylvania) and an undergraduate degree from Carnegie Mellon University.
|
|
Jonathan M. Eckard
|
Jonathan M. Eckard occupies the position of Chief Scientific Affairs Officer at Tyme Technologies, Inc.
In the past Dr. Eckard held the position of Biotechnology Equity Research Analyst at Leerink Swann & Co., Biotechnology Analyst at Barclays Capital, Inc., Associate at HSBC Securities USA, Inc., Biotechnology Analyst at Citigroup Global Markets, Inc. (Broker) and Graduate Research Assistant at New York University School of Medicine.
Dr. Eckard received an undergraduate degree from The Ohio University and a doctorate and a graduate degree from New York University School of Medicine.
|
|
David P. Carberry
|
David P. Carberry is on the board of Tyme Technologies, Inc. In his past career he was Vice President-Finance of Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance of Johnson & Johnson-Merck Consumer Pharmaceuticals Co., Chief Financial Officer & Vice President-Finance at Johnson & Johnson Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance at Independence Technology LLC and Chief Financial Officer at Aldagen, Inc.
David P. Carberry received an MBA from Drexel University and an undergraduate degree from LaSalle University.
|
|
Timothy C. Tyson
|
Timothy C. Tyson is a businessperson who founded Thayer Leader Development Group, Inc. and who has been the head of 8 different companies. Currently, he is Chairman at Icagen-T, Inc., Chairman & Chief Executive Officer at Avara Pharmaceutical Services, Inc., Chairman & Chief Executive Officer at Avara Norman Pharmaceutical Services, Inc. (a subsidiary of Avara Pharmaceutical Services, Inc.), Chairman at Icagen, Inc. and President of Alkaloida Chemical Co. Ltd. Mr. Tyson is also on the board of Tyme Technologies, Inc., Tyme, Inc. and ICN Hungary Co. Ltd. and Chief Executive Officer-Roundtable at the University of California, Irvine.
In the past he was Executive Chairman of Laurus Labs Ltd., Vice President & General Manager at GlaxoSmithKline Plc and President-Global Manufacturing & Supply at Glaxo Wellcome Plc (a subsidiary of GlaxoSmithKline Plc), Operations Manager at Procter & Gamble Co., Chairman for Aptuit LLC, President & Chief Executive Officer for Valeant Pharmaceuticals International Corp. and Director-Leadership Forum at International Society for Pharmaceutical Engineering.
Mr. Tyson received an MBA and a graduate degree from Jacksonville State University and an undergraduate degree from US Military Academy.
|
|
Tommy George Thompson
|
Mr. Tommy G. Thompson is a Chairman at Vital Decisions LLC, a Chairman-Trustees Board at Physicians Realty Trust, a Chairman at TherapeuticsMD, Inc., an Independent Director at United Therapeutics Corp., an Independent Director at Centene Corp., a Chairman & Chief Executive Officer at Thompson Holdings, Inc., a Member at State Bar of Wisconsin, a Member at The District of Columbia Bar and an Operating Partner at Windrose Health Investors LLC. He is on the Board of Directors at Tyme Technologies, Inc., United Therapeutics Corp., Centene Corp., Accordia Global Health Foundation, Armada Media Corp., Cleveland HeartLab, Inc. and Medical Missions For Children, Inc. Mr. Thompson was previously employed as a Chairman by Stayhealthy, Inc., an Independent Director by Cytori Therapeutics, Inc., an Independent Director by Cancer Genetics, Inc., a Chairman by AGA Medical Holdings, Inc., an Independent Director by C.R. Bard, Inc. (New Jersey), a Chairman by AGA Medical Corp., a Chairman by CareView Communications, Inc., a Senior Partner by Akin, Gump, Strauss, Hauer & Feld LLP, an Independent Chairman by The Deloitte Center for Health Solutions, a Chairman by Logistics Health, Inc., a Chairman by The Global Fund to Fight AIDS, Tuberculosis & Malaria, a Secretary & Governor by US Department of Health & Human Services (DC), a Governor by State of Wisconsin, a Venture Partner by Burrill & Co. LLC, a Chairman by Education Commission of the States, a Chairman by Midwestern Governors Conference, and a Chairman by National Governors Association. He also served on the board at Tyme, Inc., Tenex Health, Inc., CNS Response, Inc., SpectraScience, Inc., Medco Health Solutions, Inc., PURE Bioscience, Inc., VeriChip Corp., Harmony Information Systems, Inc., Picis, Inc., ProCure Treatment Centers, Inc., Voyager Pharmaceutical Corp. and X-Shares Advisors LLC. He received his undergraduate degree from the University of Wisconsin and a graduate degree from the University of Wisconsin.
|
|
James Biehl
|
James Biehl is on the board of Tyme Technologies, Inc. and Member of American Bar Association, Member of New Jersey State Bar Association, Member of Philadelphia Bar Association, Member of Pennsylvania State Bar Association and Partner at Drinker Biddle & Reath LLP.
Mr. Biehl received a graduate degree from Temple University (Pennsylvania) and an undergraduate degree from Carnegie Mellon University.
|
|
Jonathan M. Eckard
|
Jonathan M. Eckard occupies the position of Chief Scientific Affairs Officer at Tyme Technologies, Inc.
In the past Dr. Eckard held the position of Biotechnology Equity Research Analyst at Leerink Swann & Co., Biotechnology Analyst at Barclays Capital, Inc., Associate at HSBC Securities USA, Inc., Biotechnology Analyst at Citigroup Global Markets, Inc. (Broker) and Graduate Research Assistant at New York University School of Medicine.
Dr. Eckard received an undergraduate degree from The Ohio University and a doctorate and a graduate degree from New York University School of Medicine.
|
|
David P. Carberry
|
David P. Carberry is on the board of Tyme Technologies, Inc. In his past career he was Vice President-Finance of Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance of Johnson & Johnson-Merck Consumer Pharmaceuticals Co., Chief Financial Officer & Vice President-Finance at Johnson & Johnson Health Care Systems, Inc., Chief Financial Officer & Vice President-Finance at Independence Technology LLC and Chief Financial Officer at Aldagen, Inc.
David P. Carberry received an MBA from Drexel University and an undergraduate degree from LaSalle University.
|
高管交易状态
持股状况
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
|---|---|---|---|---|---|
|
Invesco Advisers, Inc.
|
79252
|
0.08%
|
79252
|
--
|
2018-06-30
|
|
Northern Trust Investments N A
|
373596
|
0.37%
|
373596
|
--
|
2018-06-30
|
|
State Street Corp
|
585991
|
0.58%
|
585991
|
--
|
2018-06-30
|
|
Millennium Management LLC
|
900000
|
0.89%
|
-651315
|
-41.98%
|
2018-06-30
|
|
Farallon Capital Management, L.L.C.
|
948390
|
0.94%
|
-481899
|
-33.69%
|
2018-06-30
|
|
Ardsley Advisory Partners
|
1033500
|
1.02%
|
98500
|
10.53%
|
2018-06-30
|
|
Vanguard Group Inc
|
1165289
|
1.15%
|
134903
|
13.09%
|
2018-06-30
|
|
BlackRock Inc
|
1649435
|
1.63%
|
1649435
|
--
|
2018-06-30
|
|
Healthcare Value Capital LLC
|
2075000
|
2.05%
|
--
|
--
|
2018-06-30
|
|
BlackRock Institutional Trust Company NA
|
345118
|
0.34%
|
345118
|
--
|
2018-06-30
|
|
HighTower Advisors, LLC
|
340000
|
0.34%
|
--
|
--
|
2018-03-31
|
|
Weiss Multi-Strategy Advisers Llc
|
155000
|
0.15%
|
-35000
|
-18.42%
|
2018-06-30
|
|
TIAA-CREF Investment Management LLC
|
84231
|
0.08%
|
84231
|
--
|
2018-06-30
|
|
Morgan Stanley & Co Inc
|
89619
|
0.09%
|
76784
|
598.24%
|
2018-06-30
|
|
Northern Trust Asset Management
|
101260
|
0.10%
|
-540
|
-0.53%
|
2018-07-31
|
|
1492 Capital Management, LLC
|
96881
|
0.10%
|
26681
|
38.01%
|
2018-06-30
|
|
Perkins Capital Management Inc
|
101050
|
0.10%
|
77550
|
330.00%
|
2018-06-30
|
|
Moore Capital Management, LP
|
150000
|
0.15%
|
150000
|
--
|
2018-03-31
|
|
Geode Capital Management, LLC
|
108508
|
0.11%
|
108508
|
--
|
2018-06-30
|
|
Family Management Corporation
|
140000
|
0.14%
|
--
|
--
|
2018-06-30
|
|
Morgan Stanley Smith Barney LLC
|
76107
|
0.08%
|
40061
|
111.14%
|
2018-06-30
|
|
Charles Schwab Investment Management Inc
|
78400
|
0.08%
|
78400
|
--
|
2018-06-30
|
|
Teachers Advisors Inc
|
55310
|
0.05%
|
55310
|
--
|
2018-06-30
|
|
California State Teachers Retirement Sys
|
64288
|
0.06%
|
64288
|
--
|
2018-06-30
|
|
BNY Mellon Investment Management
|
71539
|
0.07%
|
71539
|
--
|
2018-06-30
|
|
FMG LLC
|
87851
|
0.09%
|
87851
|
--
|
2018-06-30
|
|
Susquehanna Financial Group, LLLP
|
97846
|
0.10%
|
97846
|
--
|
2018-03-31
|
|
BlackRock
|
95228
|
0.09%
|
95228
|
--
|
2018-06-30
|
|
Goldman, Sachs & Co.
|
280868
|
0.28%
|
264145
|
1579.53%
|
2018-03-31
|
|
BlackRock Fund Advisors
|
1428759
|
1.12%
|
-142
|
-0.01%
|
2018-08-23
|
|
OPERS
|
53984
|
0.05%
|
53984
|
--
|
2018-06-30
|
|
Jennison Associates LLC
|
300000
|
0.30%
|
300000
|
--
|
2018-03-31
|
|
UBS O'Connor LLC
|
71233
|
0.07%
|
71233
|
--
|
2018-03-31
|
|
Tudor Investment Corp Et AL
|
50000
|
0.05%
|
50000
|
--
|
2018-03-31
|
|
Northern Trust Investments Inc
|
24714
|
0.02%
|
24714
|
--
|
2018-06-30
|
|
Jefferies & Company Inc
|
40800
|
0.04%
|
40800
|
--
|
2018-03-31
|
|
Deutsche Asset & Wealth Management Investment GmbH
|
13681
|
0.01%
|
--
|
--
|
2018-07-05
|
|
Verition Fund Managegment, LLC
|
17902
|
0.02%
|
17902
|
--
|
2018-03-31
|
|
Wells Fargo & Co
|
17302
|
0.02%
|
-831
|
-4.58%
|
2018-03-31
|
|
GLG Partners LP
|
23820
|
0.03%
|
23820
|
--
|
2017-12-31
|
|
Franklin Street Advisors Inc.
|
31000
|
0.03%
|
31000
|
--
|
2017-12-31
|
|
UBS Securities LLC
|
12468
|
0.01%
|
-1146
|
-8.42%
|
2018-03-31
|
|
Asset Planning Services Ltd
|
5000
|
0.01%
|
--
|
--
|
2017-12-31
|
|
Concept Capital Markets, LLC
|
5000
|
0.01%
|
--
|
--
|
2017-12-31
|
|
Susquehanna International Group, LLP
|
97846
|
0.10%
|
97846
|
--
|
2018-03-31
|
|
Wells Fargo Advisors, LLC
|
2850
|
--
|
--
|
--
|
2018-03-31
|
|
Royal Bank Of Canada
|
1000
|
--
|
--
|
--
|
2017-12-31
|
|
Wells Fargo Bank NA
|
8617
|
0.01%
|
420
|
5.12%
|
2018-03-31
|
|
Credit Suisse First Boston (CSFB)
|
23820
|
0.03%
|
23820
|
--
|
2017-12-31
|
|
BlueCrest Capital Management Ltd.
|
38708
|
0.04%
|
38708
|
--
|
2017-12-31
|
|
Wells Fargo Funds Management LLC
|
7352
|
0.01%
|
-1175
|
-13.78%
|
2018-01-31
|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
|---|---|---|---|---|---|
|
Vanguard Russell 2000 Growth ETF
|
30145
|
0.03%
|
--
|
--
|
2018-07-31
|
|
Schwab Small Cap Index
|
78400
|
0.08%
|
--
|
--
|
2018-07-31
|
|
CREF Stock R1
|
84231
|
0.08%
|
--
|
--
|
2018-07-31
|
|
Invesco All Cap Market Neutral A
|
79252
|
0.08%
|
79252
|
--
|
2018-06-30
|
|
iShares Micro-Cap
|
111070
|
0.11%
|
--
|
--
|
2018-09-12
|
|
Northern Trust Russell 2000 Index Fund - DC - Non-Lending
|
101260
|
0.10%
|
-540
|
-0.53%
|
2018-07-31
|
|
Wells Fargo Traditional Sm Cap Gr A
|
97709
|
0.10%
|
97709
|
--
|
2018-07-31
|
|
iShares Russell 2000 Growth
|
414668
|
0.42%
|
-400
|
-0.10%
|
2018-09-12
|
|
Vanguard Total Stock Mkt Idx
|
926156
|
0.91%
|
--
|
--
|
2018-07-31
|
|
The Vanguard Russell 2000 Growth Index
|
74328
|
0.07%
|
--
|
--
|
2018-07-31
|
|
BlackRock Russell 2500
|
60600
|
0.06%
|
60600
|
--
|
2018-06-30
|
|
AXA 2000 Managed Volatility K
|
62733
|
0.06%
|
4638
|
7.98%
|
2018-07-31
|
|
Master Small Cap Index
|
30530
|
0.03%
|
2257
|
7.98%
|
2018-07-31
|
|
BNY Mellon EB DL Small Cap SIF
|
29137
|
0.03%
|
29137
|
--
|
2018-06-30
|
|
Vanguard Balanced Index Inv
|
32398
|
0.03%
|
--
|
--
|
2018-07-31
|
|
Vanguard Russell 2000 ETF
|
47397
|
0.05%
|
882
|
1.90%
|
2018-07-31
|
|
TIAA-CREF Small-Cap Blend Idx Inst
|
51255
|
0.05%
|
--
|
--
|
2018-07-31
|
|
LVIP SSgA Small Cap Index Std
|
48800
|
0.05%
|
48800
|
--
|
2018-06-30
|
|
Vanguard Instl Ttl Stk Mkt Idx InstlPls
|
55747
|
0.06%
|
--
|
--
|
2018-07-31
|
|
BlackRock Russell 2000
|
53984
|
0.05%
|
53984
|
--
|
2018-06-30
|
|
Northern Small Cap Index
|
24714
|
0.02%
|
24714
|
--
|
2018-06-30
|
|
Pacific Select Small-Cap Index I
|
15262
|
0.02%
|
15262
|
--
|
2018-06-30
|
|
Voya Russell Small Cap Index Port I
|
19380
|
0.02%
|
19380
|
--
|
2018-06-30
|
|
iShares Russell 3000
|
24555
|
0.02%
|
--
|
--
|
2018-08-03
|
|
Nationwide Small Cap Index A
|
7355
|
0.01%
|
7355
|
--
|
2018-06-30
|
|
Principal SmallCap Growth I Instl
|
6265
|
0.01%
|
6265
|
--
|
2018-06-30
|
|
State Street Small/Mid Cap Equity Index
|
5200
|
0.01%
|
5200
|
--
|
2018-06-30
|
|
ProShares Ultra Russell2000
|
3721
|
--
|
3721
|
--
|
2018-06-30
|
|
Weiss Alternative Balanced Risk I
|
3515
|
--
|
3515
|
--
|
2018-03-31
|
|
PowerShares Russell 2000 Equal Wt ETF
|
2189
|
--
|
--
|
--
|
2018-07-12
|
|
ProShares UltraPro Russell2000
|
2005
|
--
|
2005
|
--
|
2018-06-30
|
|
Wells Fargo Dow Jones Target 2030 A
|
1223
|
--
|
-204
|
-14.30%
|
2018-05-31
|
|
Wells Fargo Dow Jones Target 2040 A
|
1316
|
--
|
-195
|
-12.91%
|
2018-05-31
|
|
GE Investments Total Return 1
|
1007
|
--
|
1007
|
--
|
2018-06-30
|
|
Wells Fargo Dow Jones Target 2050 R6
|
763
|
--
|
-118
|
-13.39%
|
2018-05-31
|
|
Wells Fargo Dow Jones Target 2020 A
|
718
|
--
|
-132
|
-15.53%
|
2018-05-31
|
|
Wells Fargo Dow Jones Target 2035 R6
|
640
|
--
|
-58
|
-8.31%
|
2018-05-31
|
|
Wells Fargo Dow Jones Target 2015 R6
|
115
|
--
|
-14
|
-10.85%
|
2018-05-31
|
|
Wells Fargo Dow Jones Target 2055 R6
|
170
|
--
|
-10
|
-5.56%
|
2018-04-30
|
|
Wells Fargo Dow Jones Target 2045 R6
|
509
|
--
|
-34
|
-6.26%
|
2018-04-30
|
|
Wells Fargo Dow Jones Target 2025 R6
|
554
|
--
|
-34
|
-5.78%
|
2018-04-30
|
|
Wells Fargo Dow Jones Target 2010 A
|
95
|
--
|
-9
|
-8.65%
|
2018-04-30
|
|
Wells Fargo Dow Jones Target 2060 A
|
50
|
--
|
1
|
2.04%
|
2018-04-30
|
|
Wells Fargo Dow Jones Target Today A
|
80
|
--
|
-6
|
-6.98%
|
2018-04-30
|
